Biochemical Markers of Bone Fragility in Patients With Diabetes
The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · e923-e936
DOI: 10.1210/clinem/dgad255 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.05.2023. Verfasst von Christian Meier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
The risk of fragility fractures is increased in both type 1 and type 2 diabetes. Numerous biochemical markers reflecting bone and/or glucose metabolism have been evaluated in this context.
Objective
This review summarizes current data on biochemical markers in relation to bone fragility and fracture risk in diabetes.
Methods
A group of experts from the International Osteoporosis Foundation and European Calcified Tissue Society reviewed the literature focusing on biochemical markers, diabetes, diabetes treatments, and bone in adults.
Results
Although bone resorption and bone formation markers are low and poorly predictive of fracture risk in diabetes, osteoporosis drugs seem to change bone turnover markers (BTMs) in diabetics similarly to nondiabetics, with similar reductions in fracture risk. Several other biochemical markers related to bone and glucose metabolism have been correlated with bone mineral density and/or fracture risk in diabetes, including osteocyte-related markers such as sclerostin, glycated hemoglobin A1c (HbA1c) and advanced glycation end products, inflammatory markers, and adipokines, as well as insulin-like growth factor-1 and calciotropic hormones.
Conclusion
Several biochemical markers and hormonal levels related to bone and/or glucose metabolism have been associated with skeletal parameters in diabetes. Currently, only HbA1c levels seem to provide a reliable estimate of fracture risk, while BTMs could be used to monitor the effects of antiosteoporosis therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.
- Academic Unit of Bone Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK.
- International Osteoporosis Foundation (IOF), Nyon, Switzerland.
- Department of Medicine and Rheumatology, Davis School of Medicine, University of California, Sacramento, CA, USA.
- Chair for Biomarkers of Chronic Diseases, Department of Biochemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Aichi, Japan.
ORCID-Profile: Christian Meier, Richard Eastell, Ghada El-Hajj Fuleihan, Serge Ferrari
Zitieren
APA
Meier, C., Eastell, R., Pierroz, D. D., Lane, N. E., Al-Daghri, N., Suzuki, A., Napoli, N., Mithal, A., Chakhtoura, M., El-Hajj Fuleihan, G., & Ferrari, S. (2023). Biochemical Markers of Bone Fragility in Patients With Diabetes. The Journal of Clinical Endocrinology & Metabolism, 108(10), e923-e936. https://doi.org/10.1210/clinem/dgad255
Vancouver
Meier C, Eastell R, Pierroz DD, Lane NE, Al-Daghri N, Suzuki A, et al. Biochemical Markers of Bone Fragility in Patients With Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):e923-e936. doi:10.1210/clinem/dgad255
BibTeX
@article{Meier2023,
author = {Meier, Christian and Eastell, Richard and Pierroz, Dominique D and Lane, Nancy E and Al-Daghri, Nasser and Suzuki, Atsushi and Napoli, Nicola and Mithal, Ambrish and Chakhtoura, Marlene and El-Hajj Fuleihan, Ghada and Ferrari, Serge},
title = {Biochemical Markers of Bone Fragility in Patients With Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {10},
pages = {e923--e936},
doi = {10.1210/clinem/dgad255}
}
EUVIMED